The application relates to application of miRNA and / or a miRNA
agonist in preparation of a
medicine for preventing and / or treating
myocardial ischemia-
reperfusion injury, and belongs to the technical field of biological
medicine. The
medicine is administered through
skeletal muscle injection, is secreted to a circulation
system after expression on the
skeletal muscle, is delivered to heart tissue by taking
extracellular vesicles as carriers, and thus regulates
myocardial cell functions. According to the
animal model verification result, the miRNA can be delivered to the heart by the
extracellular vesicles secreted by the
skeletal muscle through injection of the medicine into the skeletal
muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the
myocardial infarction area is effectively reduced,
myocardial cell apoptosis is inhibited,
myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of
myocardial ischemia-
reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of
heart failure treatment medicines.